Ichhpujani Parul, Ramasubramanian Aparna, Kaushik Sushmita, Pandav Surinder S
Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Can J Ophthalmol. 2007 Dec;42(6):812-5. doi: 10.3129/i07-160.
Recent research has shown that a large number of growth factors are responsible for neovascularization. Vascular endothelial growth factor has been identified as playing a key role in ocular angiogenesis. Bevacizumab, a humanized monoclonal antibody that binds to all isoforms of vascular endothelial growth factor, has shown promising results in regression of neovascularization. The use of bevacizumab has been reported extensively in various retinal pathologies, including proliferative diabetic retinopathy, cystoid macular edema, neovascular age-related macular degeneration, and neovascular glaucoma, but the clinical use in glaucoma is not yet clear. Glaucoma filtering surgery entails fashioning an external filter for aqueous drainage, and a prerequisite to its optimum functioning is a patent filtering bleb. Since fibroblast function and growth of new vessels is a component of healing of the bleb, there have been attempts to retard this healing by the use of bevacizumab. This article reviews current clinical studies documenting the use of bevacizumab in glaucoma.
近期研究表明，大量生长因子与新生血管形成有关。血管内皮生长因子已被确定在眼部血管生成中起关键作用。贝伐单抗是一种可与血管内皮生长因子的所有亚型结合的人源化单克隆抗体，在新生血管消退方面已显示出有前景的结果。贝伐单抗在各种视网膜病变中的应用已有广泛报道，包括增殖性糖尿病视网膜病变、黄斑囊样水肿、新生血管性年龄相关性黄斑变性和新生血管性青光眼，但在青光眼方面的临床应用尚不清楚。青光眼滤过手术需要构建一个用于房水引流的外部滤过通道，其最佳功能的一个先决条件是有一个通畅的滤过泡。由于成纤维细胞功能和新血管生长是滤过泡愈合的一个组成部分，因此人们尝试通过使用贝伐单抗来延缓这种愈合。本文综述了目前记录贝伐单抗在青光眼治疗中应用的临床研究。
